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How did the study come about?
The metabolic syndrome includes presence of several
metabolic risk factors, such as obesity, hypertension,
insulin resistance/hyperglycaemia and dyslipidaemia.
1
These factors have, separately and jointly, been asso-
ciated with an increased risk of cardiovascular dis-
eases.
2–4 To date, little is known about the metabolic
syndrome and cancer risk.
5 Recent prospective studies
have either focused on the association between the
metabolic syndrome and risk of specific cancers,
mainly colorectal and prostate cancer, or between
a single factor in the metabolic syndrome and cancer
risk.
5 It remains to be elucidated if factors within
the metabolic syndrome act in synergy on the risk of
cancer.
In 2006, we initiated the Metabolic syndrome and
Cancer project (Me-Can) in order to create a large
pooled cohort to investigate factors of the metabolic
syndrome on the association with cancer risk.
Existing cohorts in Norway, Austria and Sweden were
included in the project. The cohorts were: in Norway,
the Oslo study I (Oslo), the Norwegian Counties Study
(NCS), the Cohort of Norway (CONOR) and the Age 40
programme (40-years); in Austria, the Vorarlberg
Health Monitoring and Prevention Programme
(VHM&PP); and in Sweden, the Va ¨sterbotten
Intervention Project (VIP) and the Malmo ¨ Preventive
Project (MPP) (Figure 1). The co-ordinating centre is
at the Department of Surgical and Perioperative
sciences, Umea ˚ University, Sweden, and the Me-Can
database is stored at the Oncological Centre, Umea ˚
University, Sweden. The Me-Can project was approved
by ethical committees in the respective countries.
The purpose of Me-Can
The aim of Me-Can studies is to investigate the rela-
tion between factors in the metabolic syndrome and
cancer risk. Key exposure factors are body mass index
(BMI), blood pressure, blood glucose and serum levels
of total cholesterol and triglycerides. The specific pur-
pose of the Me-Can project is to study the effect of
these factors, separately and combined, on the asso-
ciation with risk of cancer overall and of specific
cancer sites among men and women, and to use
both incident and fatal cancer as endpoints.
Who is in the sample?
All subjects in the Me-Can cohorts underwent one or
more health examination(s) and, except for in the
VHM&PP, participants were asked to fill in a ques-
tionnaire in connection with the examination. The
questionnaires covered lifestyle factors and various
topics of specific interest for each programme. In
the VHM&PP, the examining physician asked about
lifestyle issues and answers were recorded; however,
tobacco use is the only lifestyle factor with sufficient
validity and coverage among participants for use in
studies.
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660Norwegian cohorts
The Norwegian cohorts were all initiated by the
Norwegian Institute of Public Health, or the former
National Health Screening Service in Norway (now
part of the Norwegian Institute of Public Health),
and thus, the design of these surveys were similar.
The Oslo study I (Oslo), 1972–73
The Oslo study I is the first of two rounds of surveys
conducted among men in Oslo, the capital city of
Norway.
6,7 All men aged 40–49 years and a random
selection (7%) of men aged 20–39 years were invited
to attend a health survey programme during the
period 1972–73. The purpose was to study the preven-
tion and epidemiology of cardiovascular diseases. The
attendance rate in the Oslo study I was 60%; nearly
18000 individuals participated in the study. Data
from the second round of the Oslo study, conducted
in 2000, are part of the CONOR study.
The Norwegian Counties Study, 1974–88
Screening for cardiovascular disease prevention was
performed in the Norwegian counties, Finnmark,
Figure 1 Map with location of subcohorts included in Me-Can. The 40-year cohort includes all counties in Norway
(all grey- and black-marked areas in Norway), NCS includes areas and , the CONOR includes areas and , and further
cohorts (marked in black) are; Oslo I, VHM&PP, VIP and the MPP
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1974–78, 1977–83 and 1985–88.
8,9 All residents in
these counties aged 35–49 years and a random
sample of 20–34-year-old subjects were invited to
the screening in 1974–78. The sample invited to the
second and third screening was a combination of pre-
vious participants and new cohorts. The attendance
rate in the screening periods and the counties was
between 78 and 90% and altogether, approximately
93 000 individuals participated in the NCS.
The Cohort of Norway, 1994–2003
The CONOR was established by the Norwegian
Ministry of Health and is a research collaboration
between the Norwegian Institute of Public Health
and the Universities of Bergen, Oslo, Tromsø and
Trondheim.
10 The purpose of the establishment of
CONOR was to set up a cohort that included core
survey data and stored blood samples for future
research on aetiological factors for a variety of dis-
eases. A standardized protocol was used for all
common measurements in surveys included in
CONOR. Several surveys from different regions in
Norway, and within different age groups, provide
data for the CONOR; the first data are from the
year 1994. The attendance rate in CONOR surveys
was on average 56% (range: 30–76% between surveys)
and altogether, 173 236 individuals participated in the
CONOR. A smaller proportion of participants had two
or more health examinations.
The 40-year cohort (40-year), 1985–99
The Age 40-programme was ongoing in Norway
between 1985 and 1999 and by 1993, the programme
covered all counties in Norway.
11 Every 3 years, all
40–42-year-old residents of a county were invited to
a health examination for monitoring of risk factors of
cardiovascular diseases and epidemiological research.
In some counties, broader age groups were invited.
The attendance rate was on average 69% for the
whole period 1985–99, and the number of participants
was nearly 420 000. The attendance rate has declined
over time; it was 62% in the period 1994–99. During
this period, 140 000 persons participated in the Age
40-programme, and observations from these years will
be used as baseline in Me-Can studies.
The Austrian cohort
The Vorarlberg Health Monitoring and
Prevention Programme, 1985–2005
The VHM&PP is a population-based risk factor
surveillance programme in Vorarlberg, the western-
most province in Austria.
12 The purpose of the pro-
gramme was to prevent chronic diseases, foremost
cardiovascular diseases and cancer, and it was
routinely performed by the Agency for Social and
Preventive Medicine. All adult residents in the
region were invited by written invitations, television,
radio or newspapers, to participate in a health
examination up to once a year. Since 1985, more
than two-thirds of the population of the province par-
ticipated in the programme. Data from the years
1985–2003 are included in Me-Can, and during
these years the attendance rate in the VHM&PP was
66% and roughly 176000 persons participated in
the programme.
Swedish cohorts
The Va ¨sterbotten Intervention Project, 1985
and ongoing
The VIP is an ongoing project aiming for prevention
of diabetes and cardiovascular disease in residents of
Va ¨sterbotten county in the north of Sweden.
13,14
Since 1985, all residents have been invited for a
health check-up at 40, 50 and 60 years of age, and
during the first 10 years of the project, residents were
also invited at the age of 30. The attendance rate has
been 60% on average over the years. By the end of
2006, approximately 86000 men and women had par-
ticipated in the VIP.
The Malmo ¨ Preventive Project, 1974–92
Middle-aged men and women in the city of Malmo ¨ in
southern Sweden, were invited to a screening pro-
gramme for prevention of cardiovascular disease and
alcohol abuse.
15,16 Screenings were carried out
between 1974 and 1992, to which all residents
within predefined birth cohorts, born between 1921
and 1949, were invited. The attendance rate was on
average 71% over the years. A total of 33 346 men and
women participated in the baseline screening, and
5722 of these men (born 1926–38) and 387 women
(born in 1931) participated in a second screening in
1981–89. The examination at the second screening
was similar to that of the first screening.
What has been measured?
In all Me-Can cohorts, measurements of height,
weight and systolic and diastolic blood pressure
have been performed, and blood/plasma/serum levels
of glucose, total cholesterol and triglycerides have
been analysed. However, glucose levels were not mea-
sured throughout all years and in all surveys in
Norway, and before the year 2001, triglycerides were
not measured consequently in all participants in the
VIP. There are no other data available on metabolic
factors or factors related to the MetS with sufficient
coverage in all Me-Can cohorts.
A description of measurement methods is shown in
Table 1. Anthropometric measurements were con-
ducted in a similar way in all Me-Can cohorts, with
participants wearing light indoor clothes and no
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cohorts for measurement of blood pressure. In the
Norwegian cohorts, participants were not requested
to fast before the health examination, and thus,
most blood samples were drawn in a non-fasting
state. In the VHM&PP and the MPP, participants
were asked to fast overnight before the health exam-
ination, which also became standard procedure in
1992 in the VIP. In the VHM&PP, plasma glucose
was measured after an oral glucose tolerance test
(OGTT) during the first 3 years, and from 1988, fast-
ing glucose was measured. Glucose levels were mea-
sured in serum in the Norwegian cohorts, in plasma
in the VHM&PP and the VIP, and in whole blood in
the MPP. Determination of lipid levels was performed
in serum in all cohorts.
Data management and selection
of subjects/observations for
Me-Can studies
Altogether, the Me-Can study file includes 940 060
subjects with data from 1 600 296 health examina-
tions, and after data cleaning and selection of subjects
and observations, data from a total of 578 700 sub-
jects will be used in Me-Can studies on the metabolic
syndrome and cancer risk (Figure 2). From the origi-
nal data files, subjects with an incomplete personal
identity number were excluded, and of subjects
included in both the VIP and the MPP, the subject
in the doublet with the least complete data was
excluded. One man with ovarian cancer recorded
and seven women with prostate or testicular cancer
recorded, were excluded. Missing data for day and
month were substituted with Day 15 for missing
day and June 30 for missing month and day, and
observations with dates that did not match were
excluded. Observations with a malignant cancer
before the health examination were also excluded
at baseline. Observations with extreme values for
exposure factors were excluded as follows: height
<100 or 4250cm, weight <35 or 4250kg, BMI <15
or460kg/m
2, systolic blood pressure <75mmHg, dia-
stolic blood pressure <40mmHg, systolic blood pres-
sure <diastolic blood pressure, glucose <1mmol/l,
cholesterol <0.5 or 420mmol/l, triglycerides <0.05
or 435mmol/l. We also excluded observations with
data missing for height and weight. Further, we
excluded examinations (observations) that had been
performed <1 year before the end of follow-up for
incident cancer, and examinations in the VHM&PP
that had been performed before 1988, during which
post-load glucose had been measured instead of fast-
ing glucose. Observations with data missing for fast-
ing status were also excluded. A total of 904 432
subjects with 1 440 411 observations remained eligible
for use in studies of the metabolic syndrome and
cancer risk. In subjects with several observations
available, we selected the first observation with a fast-
ing blood sample and with smoking status reported as
the baseline observation. After this selection, 70% of
subjects in the study file were from the Norwegian
cohorts. A policy imposed by the Norwegian
Institute of Public Health restricts Me-Can studies
not to exceed  50% of subjects from the Norwegian
cohorts in the total study population. Thus, to reduce
the proportion, we further excluded subjects from
Norway without data on all the exposure factors
(BMI, blood pressure, glucose, cholesterol and trigly-
cerides) and those without data on smoking status.
Missing data for glucose was the cause for exclusion
in 99% of subjects. The final data set to be used in
Me-Can studies includes 578 700 subjects, 289 866
(50%) men and 288 834 (50%) women (Table 2). Of
these subjects, data from two or more health exam-
inations are available for 207 890 (36%) subjects,
which will be used to calculate random error in expo-
sure factors to assess more accurate estimates of asso-
ciations with cancer risk.
20
Follow-up
Nationwide registers in Norway, Austria and Sweden
will be used for follow-up of subjects. Linkages have
been performed to the cancer registers, which have an
almost complete coverage of cancer cases in Norway
21
and Sweden,
22 and the cancer register in Austria has
also shown a high coverage of diagnosed cancers.
23
The cohorts have also been linked to the respective
National Cause of Death Register, and in Norway
and Sweden, to the Register of the Total Population
and Population Changes, for vital status (data not
available in Austria). To reduce the possibility of
reverse causation, follow-up in Me-Can studies will
consequently start 1 year after the baseline examina-
tion, which with the current linkage dates resulted in
37000 incident cancers and 13000 fatal cancers
during follow-up. The Me-Can project has the statis-
tical power of 80%, with an alfa level of 5%, to detect
a relative risk for the fifth versus first quintile of 1.05
for all cancer sites combined (37000 cases), 1.13 for
sites with 5000 cases (prostate, breast), 1.33 for sites
with 1000 cases (kidney, endometrium) and 1.79 for
sites with 250 cases (oesophagus, liver). The power
can be increased by using models that utilize all
data, i.e. continuous levels, for estimation.
What are the main strengths and
weaknesses?
The main strength of the Me-Can project is the large
data set from a number of population-based surveys,
with almost complete coverage of data for exposure
factors in all cohorts, and the access of data on
repeated health examinations for a substantial
number of the subjects. Another strength is the use
of high-quality national registers for follow-up of
664 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYsubjects. Limitations of the project are the lack of
detailed data on possible confounders and on
tumour characteristics and cancer treatment, and
that measurement methods of exposure factors dif-
fered between the cohorts.
Where can I find out more?
Further information about cohorts in Me-Can can be
found in the reference list, and for the Norwegian
cohorts, at the Norwegian Institute of Public Health
web-page: http://www.fhi.no/eway/default.aspx?pid
=233&trg=MainArea_5661&MainArea_5661=5631:
0:15,3570:1:0:0:::0.
Funding
World Cancer Research Fund (Grant 2007/09 to Me-
Can); Swedish Cancer Society (Grant 2007/693 to
Me-Can; Austrian National Bank (Grant ONEB-
12737 to VHM&PP).
Incomplete ID, doublets of subjects in the VIP-MPP, men 
diagnosed with ovarian cancer and women diagnosed with 
testis/prostate cancer: 18 subjects (31 observations) 
Date of cancer diagnosis ≤ date of health 
examination: 27 112 observations 
Observations in the VHM&PP (year 2003) and in the VIP 
(year 2006) with <1 year follow-up until last date of 
coverage of cancer diagnoses: 46 673 observations 
In subjects with ≥ 2 health examination: 
selection of the first observation with          
i) fasting state ii) data on smoking status  
904 432 subjects with 1 440 411 observations 
Extreme values for exposure 
factors: 1188 observations 
Exclusions 
Selected baseline 
observation 
Missing date or non-matching dates: death/emigration 
< cancer diagnosis, health examination ≥ end of 
follow-up for cancer, death/emigration ≤ health
examination: 241 observations 
In order to reach an  50% proportion of subjects from 
Norway in total data set: exclusion of Norwegian 
subjects with data missing for any of the exposure 
factors or for smoking status: 325 732 subjects  
BMI missing: 5171 observations 
Observations in the VHM&PP before the year 1988 (OGTT 
measures instead of fasting glucose): 76 563 observations 
Fasting status missing: 
2906 observations 
578 700 subjects with one baseline observation each 
940 060 subjects with 1 600 296 observations 
Figure 2 Description of data cleaning and selection of subjects/observations for Me-Can studies on the metabolic syndrome
and cancer risk
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